Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Clinical Trial of...

    Clinical Trial of Sirolimus balloon catheter: Cardiologist invests 60 million dollar in Device maker

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-10-13T12:30:29+05:30  |  Updated On 13 Oct 2018 12:30 PM IST
    Clinical Trial of Sirolimus balloon catheter: Cardiologist invests 60 million dollar in Device maker

    HOUSTON: An Indian-American cardiologist and entrepreneur has invested $60 million in a medical company that will support clinical trial on cardiac devices to replace the stent.


    Dr Kiran Patel's investment is for the Concept Medical Inc, a Florida-based medical device company's Investigational Device Exemption (IDE) for the world's first sirolimus-coated balloon.

    Sirolimus balloon catheter is a drug-coated balloon, which is a replacement of the stent. If a stent cannot be placed in the human body or doesn't have a good outcome, then sirolimus balloon is used.

    According to the company, the investment by the Indian American cardiologist will pave way for clinical studies to reduce the risk of heart blockages.

    Patel's investment will pay for clinical studies on cardiac devices coated with a substance that reduces the risk of heart blockages and the length of time a patient needs to take blood thinners, according to a statement issued by the company.

    Noting that cardiovascular diseases represent 31 per cent of all global deaths, Patel said that his contribution will help towards the healthcare of millions of people around the world.

    "I am excited to be a part of CMI whose research & innovative technologies will meet a major unmet need in patients with diabetes and cardiovascular diseases. This venture enables me to contribute to the millions of hearts beating around the world," Patel was quoted as saying in the release.

    A portion of the funds will also be utilised to bolster the manufacturing operations to meet the increasing demand for their products globally.
    cardiac devicescardiologistCardiovascular diseasesConcept Medical IncDr Kiran PatelHealthcareheartHOUSTONIDEIndian American cardiologistInvestigational Device ExemptionInvestmentmedical deviceSirolimus balloon cathetersirolimus-coated balloon
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok